&nbsp;

Aug 2025

Drug

trametinib

Other Name(s): Mekinist®

Quick Link(s):

Jun 2025

Drug

venetoclax

Other Name(s): Venclexta®

Quick Link(s):

Aug 2025

Regimen

TMZL

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

temozolomide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

TRAM

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria

Drugs Used:

trametinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

TOPO(W)

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Drugs Used:

topotecan

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

TMZL

Cancer Type:

Central Nervous System

Intent: Adjuvant

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

temozolomide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

TMXFRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

tamoxifen

Drugs Used:

tamoxifen,

ribociclib (Unfunded)

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

VENE+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

VENE+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia

Exceptional Access Program

venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria

Drugs Used:

oBINutuzumab,

venetoclax

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

tucatinib

Other Name(s): Tukysa™

Quick Link(s):

Feb 2025

Regimen

VENE(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria

Exceptional Access Program

venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria

Drugs Used:

venetoclax